Quantcast
Last updated on April 24, 2014 at 13:10 EDT

Latest Sulfonylurea Stories

2014-04-15 16:27:56

LONDON, April 15, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Tanzeum(TM) (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), is a biological product for the...

2014-02-14 23:20:53

Researchers say the diabetes drug does not appear to reduce the risk of bladder cancer in patients with type 2 diabetes. Raleigh, NC (PRWEB) February 14, 2014 New research conducted at the University of Pennsylvania’s Abramson Cancer Center and reported by Cancer Monthly finds that patients on the popular type 2 diabetes drug metformin (Glucophage) have about the same risk of getting bladder cancer as patients on another class of drugs called sulfonylureas . Both types of drugs carry a...

2013-12-12 20:24:44

RARITAN, N.J., Dec. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. The complete response letter related to the NDA requested additional information to support the comparability of the twice-daily...

2013-09-18 23:02:15

Western University of Health Sciences' College of Pharmacy assistant professor Olivia J. Phung, PharmD, has published an article proposing that using a certain class of diabetes medication could potentially increase risk of heart attack and other cardiovascular problems. Pomona, CA (PRWEB) September 18, 2013 College of Pharmacy assistant professor Olivia J. Phung, PharmD, has published an article proposing that using a certain class of diabetes medication could potentially increase...

2013-09-10 08:31:20

TAIPEI, Sept. 10, 2013 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead drug candidate, from the United States Patent & Trademark Office. The granted patent, US patent number 8,536,152, covers AC-201's use as a combination therapy with other existing blood glucose lowering therapy agents to treat Type II diabetes. The patent is part of TWi Biotechnology's broad...

2013-06-23 20:20:04

Phase 3 Results for INVOKANA(TM) Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure CHICAGO, June 23, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a new 52-week Phase 3 clinical study, showing 300 milligrams (mg) of INVOKANA(TM) (canagliflozin) provided greater improvements in blood glucose control compared to a commonly prescribed therapy,...

2013-06-22 12:20:16

Data presented at the American Diabetes Association 73rd Scientific Sessions® provide insights for use of linagliptin in adults with type 2 diabetes (T2D) with moderate to severe renal impairment RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels...

2013-03-29 16:21:36

INVOKANA(TM) is the first in a new class of type 2 diabetes medications available in the United States RARITAN, N.J., March 29, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA(TM) (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA(TM) is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It...

2012-11-08 08:34:44

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes) has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to a sulfonylurea in a long-term cardiovascular (CV) outcome study. Linagliptin,...

2012-09-25 02:29:13

RARITAN, N.J., Sept. 25, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) will present new Phase 3 data results evaluating canagliflozin, an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, in adult patients with type 2 diabetes at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD), from October 1-5, 2012 in Berlin, Germany. "The data we will present at EASD are the latest results from our...